Third population-based immune surveillance study used for the evaluation of immunity against SARS-CoV-2

Third population-based immune surveillance study used for the evaluation of immunity against SARS-CoV-2 - Immunity against SARS-CoV-2 in Dutch population (PIENTER Corona)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52416

Enrollment

14000

Registered

2020-03-21

Start date

2020-03-31

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 SARS-CoV-2

Interventions

None listed

Eligibility

Age

No minimum to 99 Years

Inclusion criteria

Inclusion criteria: Subject previously participated in the PIENTER 3 study (2016/17), and had indicated that they could be approached for a follow-up study, or subjects from a random age-stratified sample from the Netherlands

Exclusion criteria

Exclusion criteria: not applicable

Design outcomes

Primary

Measure	Time frame
To assess achieved immunity against COVID-19 over time across the different age groups in The Netherlands by testing a representative part of the Dutch population for the presence of SARS-Cov-2 specific antibodies in serum	—

Secondary

Measure	Time frame
To assess the quantity and quality (i.e. antibody functionality and avidity) of the antibodies raised against SARS-CoV-2 in a representative part of the Dutch population, and to identify subgroups (including risk groups) with different levels of immunity against COVID-19 To assess the development of immunity during and after the first pandemic wave and the period thereafter To assess the existence of cross-reactive antibodies against established coronavirus infections in the past To asses the antibodies in the mucosal fluid	—

Measure

Time frame

To assess the quantity and quality (i.e. antibody functionality and avidity) of the antibodies raised against SARS-CoV-2 in a representative part of the Dutch population, and to identify subgroups (including risk groups) with different levels of immunity against COVID-19 To assess the development of immunity during and after the first pandemic wave and the period thereafter To assess the existence of cross-reactive antibodies against established coronavirus infections in the past To asses the antibodies in the mucosal fluid

—

Countries

Netherlands

Outcome results